Smart Immune

Smart Immune is a clinical-stage biotechnology company specializing in the development of allogeneic T-cell progenitor therapies designed to rebuild patients’ immune systems rapidly and safely. Headquartered in Paris, the company addresses critical challenges in treating high-risk leukemia, cancer relapse post-transplant, and severe infections by delivering off-the-shelf, ready-to-use thymus-educated T-cell progenitors that regenerate a diversified, functional immune repertoire.

Its flagship SMART101 product aims to provide immune reconstitution within 100 days, significantly faster than traditional stem cell transplant methods. By harnessing ex vivo expansion of hematopoietic stem cells and a proprietary differentiation platform, Smart Immune generates large quantities of standardized, quality-controlled T-cell progenitors, overcoming limitations of donor variability and manufacturing scalability.

This approach not only improves transplant safety and reduces infection-related mortality but also broadens access to advanced immunotherapies by offering off-the-shelf solutions compatible with multiple transplant settings. Smart Immune collaborates with academic hospitals and industry partners to accelerate clinical validation and scale production under GMP conditions, seeking to transform the standard of care for immunocompromised patients worldwide.

Keywords: immunotherapy, T-cell progenitors, allogeneic, off-the-shelf cell therapy, immune reconstitution, leukemia, infections, stem cell transplant, biotech.